Home puce Elicityl against Cystic Fibrosis

Elicityl against Cystic Fibrosis

Elicityl is proud to announce that the Anti-Pyo project, accredited by the world competitiveness cluster LyonBioPôle and submitted to the 14th FUI call for projects has been selected.

The objective of the project is to develop a drug candidate to treat lung infections related to Pseudomonas aeruginosa in patients in intensive care and in patients with cystic fibrosis. This bacteria is the leading cause of infection in patients in intensive care and is responsible for 80% of mortality in patients with cystic fibrosis. The molecules developed in ANTI-PYO will have to prevent bacterial attachment to the lung surface, to facilitate their elimination by the immune system and to make them much more sensitive to standard antibiotic treatments against which the bacteria has become resistant.

Read the news

Read the press release